Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1115
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 997–1008 of 1,115 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

NCT06912087
Status at this site: Recruiting
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
Interventions
Zanzalintinib, Cetuximab, Pembrolizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Recruiting Phase 2 Interventional

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

NCT03945162
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions
Ruvidar® (TLD-1433) bladder infusion and PDT
Combination Product
Lead sponsor
Theralase® Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Active, not recruiting Not applicable Interventional

Using Technology to Address Disparities and Promote Healthcare Equity in Type 1 Diabetes Registry

NCT06899984
Site status not listed — check the official record
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Patient Navigator
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Active, not recruiting Not applicable Interventional Results available

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy

NCT04572633
Site status not listed — check the official record
View directory record Official record
Conditions
Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
Interventions
HistoSonics System
Device
Lead sponsor
HistoSonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Active, not recruiting No phase listed Observational

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

NCT06652100
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ProNephro AKI (NGAL)
Diagnostic Test
Lead sponsor
BioPorto Diagnostics
Industry
Eligibility
22 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Sacramento, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Active, not recruiting No phase listed Observational

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

NCT05714514
Site status not listed — check the official record
View directory record Official record
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Active, not recruiting Phase 1 Interventional

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05973487
Site status not listed — check the official record
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
Biological
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Active, not recruiting No phase listed Observational

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT05812027
Site status not listed — check the official record
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions
Tumor and HLA Profiling
Diagnostic Test
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Chronotype: Impact on Sleep and Metabolism

NCT03647306
Site status not listed — check the official record
View directory record Official record
Conditions
Type2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
Early Total Caloric Intake, Late Total Caloric Intake, Extended Overnight Fast
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
30 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Recruiting Not applicable Interventional

Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy

NCT06397456
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
In-Person Patient Education, Commitment to Change, Blood pressure monitoring, Written Patient Education, Text-based reinforcement for CKD self-management, Community-based education session, reinforcement for self-management, Text-based reinforcement for general health self-management
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Recruiting Phase 3 Interventional

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

NCT06499857
Status at this site: Recruiting
View directory record Official record
Conditions
Overweight or Obesity, Atrial Fibrillation
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Phoenix, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 9, 2026, 1:58 PM EST
Recruiting Not applicable Interventional

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

NCT05641844
Status at this site: Recruiting
View directory record Official record
Conditions
Anal Fistula
Interventions
RD2 Ver.02, Saline
Device · Other
Lead sponsor
RedDress Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Weston, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 9, 2026, 1:58 PM EST

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.